Regeneron Pharmaceuticals Inc REGN
Analyst Ratings
- Consensus
- Moderate Buy — 17 Buy · 8 Hold · 0 Sell (25 analysts)
- Avg. Price Target
- $903.36 (-5.8% downside)
Key Stats
- Today's Range
- $898.29 – $961.98
- 50-Day Range
- $722.02 – $991.73
- 52-Week Range
- $541.00 – $991.73
- Volume
- 1.23 million shs
- Average Volume
- 865K shs
- Market Cap
- $94.76 billion
- P/E Ratio
- —
- Dividend Yield
- 0.39%
Dividend
- Dividend Yield
- 0.39%
- Annual Dividend
- $3.76
- Payout Ratio
- —
- Ex-Dividend Date
- 2026-11-20
Short Interest
- Short Interest
- 1.82%
- Days to Cover
- 3.71
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Related Stocks
Compare head-to-head: REGN vs LLY·REGN vs JNJ·REGN vs ABBV·REGN vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.